One of a kind stock, page-12

Hi all, a few familiar faces in here, which is always encouraging. After watching the video I have some questions.

Why is an asset funded through what I presume is 2 ph2 trials by the US government so cheaply acquired by a tiny Australian biotech?

What are the recruitment numbers considering the trials are 1 centre each, and will that provide worthwhile p values?

Are they in fact ph2 or ph1?

If they are ph1, the cost of ph2 will be at least $5m each, considering the market cap, that's going to be a stretch.

100+ patients have apparently already received treatment, do we have results, are they safety or efficacy?

Three doctors running the show scares me a little. I've seen this type of work stolen cheaply at the critical junctiour before.

I have just poked my head in here, and will do my own research of course, but if the information has already been discussed I'm asking on the off chance as it will give me a better background to go looking with.

On the face of it, it looks like a pretty low risk at this tiny MC. I'm not sure advising pundits that you will go to the market for capital in March 2015 is wise, because we can take a guess that shares bought now will be dumped in February to produce an attractive VWAP if it gets traction between now and then.